Targeting MAPAKAP2(MK2) to combat inflammation by avoiding the differential regulation of anti-inflammatory genes by p38 MAPK inhibitors
R. K. Singh, R. Sodhi, S. Sharma, S. G. Dastidar, R. Tandon
The paper evaluates MK2 inhibitors as a safer alternative to p38 MAPK inhibitors for anti-inflammatory therapy by comparing their toxicity and efficacy in cell-based assays.
bioRxiv · Jul 17, 2022 · PreprintPharmacology & Toxicology